Zustand: very good. Gut/Very good: Buch bzw. Schutzumschlag mit wenigen Gebrauchsspuren an Einband, Schutzumschlag oder Seiten. / Describes a book or dust jacket that does show some signs of wear on either the binding, dust jacket or pages.
Sprache: Englisch
Verlag: Cambridge University Press, 2010
ISBN 10: 0521760585 ISBN 13: 9780521760584
Anbieter: Antiquariaat Die Sammlung, Amsterdam Zuidoost, Niederlande
Erstausgabe
Hardcover. Zustand: Fine. 1st Edition. 137 p.
Sprache: Englisch
Verlag: Cambridge University Press, 2010
ISBN 10: 0521760585 ISBN 13: 9780521760584
Anbieter: ThriftBooks-Atlanta, AUSTELL, GA, USA
Hardcover. Zustand: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less.
Sprache: Englisch
Verlag: Cambridge University Press, 2010
ISBN 10: 0521760585 ISBN 13: 9780521760584
Anbieter: WorldofBooks, Goring-By-Sea, WS, Vereinigtes Königreich
EUR 41,27
Anzahl: 1 verfügbar
In den WarenkorbHardback. Zustand: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 152,11
Anzahl: 3 verfügbar
In den WarenkorbZustand: New.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 153,31
Anzahl: 2 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 250 pages. 9.25x7.50x9.25 inches. In Stock.
Sprache: Englisch
Verlag: Cambridge University Press, 2010
ISBN 10: 0521760585 ISBN 13: 9780521760584
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.